Chamberlain Stanley D, Wilson Joseph W, Deanda Felix, Patnaik Samarjit, Redman Anikó M, Yang Bin, Shewchuk Lisa, Sabbatini Peter, Leesnitzer M Anthony, Groy Arthur, Atkins Charity, Gerding Roseanne, Hassell Anne M, Lei Huangshu, Mook Robert A, Moorthy Ganesh, Rowand Jason L, Stevens Kirk L, Kumar Rakesh, Shotwell J Brad
GlaxoSmithKline, Oncology R&D, 5 Moore Drive, 3.4184.4B, PO Box 13398, Research Triangle Park, NC 27709-3398, USA.
Bioorg Med Chem Lett. 2009 Jan 15;19(2):469-73. doi: 10.1016/j.bmcl.2008.11.046. Epub 2008 Nov 18.
The evaluation of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines as inhibitors of the IGF-1R (IGF-IR) receptor tyrosine kinase is reported. Examples demonstrate nanomolar potencies in in vitro enzyme and mechanistic cellular assays as well as promising in vivo pharmacokinetics in rat.
报道了一系列4,6-双苯胺基-1H-吡咯并[2,3-d]嘧啶作为胰岛素样生长因子1受体(IGF-1R)酪氨酸激酶抑制剂的评估情况。实例表明,其在体外酶学和细胞机制分析中具有纳摩尔级别的活性,并且在大鼠体内具有良好的药代动力学特性。